Orly Leiva, Andrew Jenkins, Rachel P Rosovsky, Rebecca K Leaf, Katayoon Goodarzi, Gabriela Hobbs
{"title":"Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms.","authors":"Orly Leiva, Andrew Jenkins, Rachel P Rosovsky, Rebecca K Leaf, Katayoon Goodarzi, Gabriela Hobbs","doi":"10.3390/hematolrep15020040","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with myeloproliferative neoplasms (MPNs) are at increased risk of cardiovascular disease (CVD), including acute coronary syndrome (ACS). However, data on long-term outcomes of patients with MPN who have had ACS and risk factors for all-cause death or CV events post-ACS hospitalization are lacking. We conducted a single-center study of 41 consecutive patients with MPN with ACS hospitalization after MPN diagnosis. After a median follow-up of 80 months after ACS hospitalization, 31 (76%) experienced death or a CV event (myocardial infarction, ischemic stroke, or heart failure hospitalization). After multivariable Cox proportional hazards regression, index ACS within 12 months of MPN diagnosis (HR 3.84, 95% CI 1.44-10.19), WBC ≥ 20 K/µL (HR 9.10, 95% CI 2.71-30.52), <i>JAK2</i> mutation (HR 3.71, 95% CI 1.22-11.22), and prior CVD (HR 2.60, 95% CI 1.12-6.08) were associated with increased death or CV events. Further studies are warranted to improve cardiovascular outcomes in this patient population.</p>","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"15 2","pages":"398-404"},"PeriodicalIF":1.1000,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298451/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/hematolrep15020040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 1
Abstract
Patients with myeloproliferative neoplasms (MPNs) are at increased risk of cardiovascular disease (CVD), including acute coronary syndrome (ACS). However, data on long-term outcomes of patients with MPN who have had ACS and risk factors for all-cause death or CV events post-ACS hospitalization are lacking. We conducted a single-center study of 41 consecutive patients with MPN with ACS hospitalization after MPN diagnosis. After a median follow-up of 80 months after ACS hospitalization, 31 (76%) experienced death or a CV event (myocardial infarction, ischemic stroke, or heart failure hospitalization). After multivariable Cox proportional hazards regression, index ACS within 12 months of MPN diagnosis (HR 3.84, 95% CI 1.44-10.19), WBC ≥ 20 K/µL (HR 9.10, 95% CI 2.71-30.52), JAK2 mutation (HR 3.71, 95% CI 1.22-11.22), and prior CVD (HR 2.60, 95% CI 1.12-6.08) were associated with increased death or CV events. Further studies are warranted to improve cardiovascular outcomes in this patient population.
骨髓增生性肿瘤(mpn)患者发生心血管疾病(CVD)的风险增加,包括急性冠状动脉综合征(ACS)。然而,缺乏关于发生ACS的MPN患者的长期结局和ACS住院后全因死亡或CV事件的危险因素的数据。我们对41例MPN确诊后ACS住院的MPN患者进行了单中心研究。在ACS住院后中位随访80个月后,31例(76%)发生死亡或心血管事件(心肌梗死、缺血性卒中或心力衰竭住院)。在多变量Cox比例风险回归后,MPN诊断后12个月内的ACS指数(HR 3.84, 95% CI 1.44-10.19)、WBC≥20 K/µL (HR 9.10, 95% CI 2.71-30.52)、JAK2突变(HR 3.71, 95% CI 1.22-11.22)和既往CVD (HR 2.60, 95% CI 1.12-6.08)与死亡或CV事件增加相关。需要进一步的研究来改善这类患者的心血管预后。